

FORM PTO-1449 (REV. 7-60)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09781-984 10/700,906			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									APPLICANT(S): Ostlack, et al.				
									FILING DATE: February 8, 2004	GROUP: 1615 11/4/03			
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	AB	3	9	3	4	4	4	6	05/22/1975	Leslie	424	22	
	AB	4	4	3	4	4	4	4	12/02/1980	Dudzinski	424	260	
	AC	4	8	6	4	3	3	3	12/28/1982	Leslie	536	56	
	AD	4	4	4	6	4	2	3	04/17/1984	Ostlack, et al.	424	22	
	AE	4	8	4	4	3	3	3	05/09/1985	Elger, et al.	424	419	
	AF	4	4	3	4	9	9	3	05/30/1989	Martani, et al.	424	488	
	AG	4	4	3	4	3	4	4	05/30/1989	Goldie, et al.	424	488	
	AH	4	8	4	4	3	3	3	05/30/1989	Elger, et al.	424	488	
↓	AI	4	4	4	4	3	3	4	07/04/1989	Elger, et al.	424	465	
HS	AJ	4	8	4	4	6	4	9	07/04/1989	Goddie, et al.	424	480	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES
													NO
HS	AP	0	8	4	3	4	4	4	09/03/1986	Europe (A3)	A61K	31/615	
HS	AL	4	3	4	4	4	4	3	06/07/1989	Europe (A1)	A61K	31/485	
HS	AN	0	8	4	4	2	4	4	11/07/1990	Europe (A2)	A61K	31/485	
HS	AN	4	0	0	1	2	4	4	01/13/2000	WO	A61K	31/00	
HS	AO	4	0	0	4	8	4	5	05/17/1990	WO	A61K	31/485	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
HS	AP	Translation of previously submitted German patent application DE 43 25 465 (2003)											
HS	AQ	Alvarez-Fuentes, et al., "Effectiveness of Repeated Administration of a New Oral Naltrexone Controlled-Release System on Morphine Analgesia"; J. Pharm Pharmacol (2001), 53; pg. 1201-1205											
HS	AR	Alvarez-Fuentes, et al., "Preclinical Study of an Oral Controlled Release Naltrexone Complex in Mice"; J. Pharm Pharmacol (2000), 52; pg. 659-663											
EXAMINER		/Humera Sheikh/						DATE CONSIDERED		01/21/2007			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 2001133	SERIAL NO.: 09/781,081 / 10/700,906					
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Oshack, et al.						
						FILING DATE: February 6, 2001	GROUP: 1615					
U.S. PATENT DOCUMENTS												
EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
HS	BO	1	8	1	4	9	1	9	07/04/1989 Leslie, et al.	424	494	
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
	BB								YES	NO		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
HS	BC	Archer, Sydney, "Historical Perspective on the Chemistry and Development of Naltrexone"; Naltrexone: Research Monograph 28 (1980) pg. 3-9										
	BD	Baum, et al., "The Impact of the Addition of Naloxone on the Use and Abuse of Pentazocine"; Public Health Reports (1987) Vol. 102, No. 4 pg. 426-429										
	BE	Rapaka, et al., "Discovery of Novel Opioid Medications"; NIDA Research Monograph 147 (1995) pg. 53-83										
	BF	Bloom, et al., "Clinical Studies with Naloxone/Methadone in a Ratio of 1:20 ⁴ ; 5 ^o National Conference on Methadone Treatment (1973) Vol 2, pg. 1342 - 1349										
	BG	Blachly, M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pg. 209-213										
	BH	Briscoe, et al., "Methocloclamox: Time Course of Changes in Alfentanil-Reinforced Responding in Rhesus Monkeys"; Psychopharmacology (2000) 148: pg. 393-399										
	BI	Abstract of Bromm, et al., "A Sensitive Method to Evaluate Effects of Analgesics in Man"; Meth and Find Exptl Clin Pharmacol 5 (8) (1983) pg. 545-551										
	BJ	Bullingham, et al., "Clinical Pharmacokinetics of Narcotic Agonist-Antagonist Drugs"; Clinical Pharm. (1983) 8: 332-343										
	BK	Calimlim, et al., "Effect of Naloxone on the Analgesic Activity of Methadone in a 1:10 Oral Combination"; Clin Pharmacol and Ther (1974) Vol. 15; No. 6 pg. 556-564										
	BL	Caruso, et al., "Methadone and Naloxone in Combination (Naldone®) for the Treatment of Heroin Addicts"; Bristol Laboratories, pg. 1336-1341F (1973)										
	BM	Cherry, Nathan I., "Opioid Analgesics"; Drugs (1996) May. 51 (5) pg. 713-737										
	BN	Chiang, et al., "Clinical Evaluation of a Naltrexone Sustained-Release Preparation"; Drug and Alcohol Dependence (1985) 16, pg. 1-8										
	BO	Chiang, et al., "Kinetics of a Naltrexone Sustained-Release Preparation"; Clin. Pharmacol Ther. (1984) Vol. 36, No. 5, pg. 704-708										
V	BP	Comer, et al., "Depot Naltrexone: Long-lasting Antagonism of the effects of heroin in humans"; Psychopharmacology (2002) 159, pg. 351-360										
HS	BO	Crabtree, et al., "Review of Naltrexone, a long-acting opiate antagonist"; Clinical Pharmacy, Vol 3 (1984) pg. 273-280										
EXAMINER	/Humera Sheikh/					DATE CONSIDERED			01/21/2007			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO: 200.1133	SERIAL NO: 09/781,081-10/200,906
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Ostlack, et al.	
						FILING DATE: February 6, 2001-1/10/03	GROUP: 1615
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HS	CA	8 8 8 8 8 8	09/19/1989	Heafield, et al.	424	461	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	CB						YES NO
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
HS	CC	Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability"; Dept. Of Neuroscience, Albert Einstein College of Medicine, Pain 82 (1999) pg. 1-11					
	CH	Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability"; Dept. Of Neuroscience, Albert Einstein College of Medicine, Pain 84 (2000) pg. 121-131					
	CE	Fink, et al., "Naloxone in Heroin Dependence"; Clin Pharm and Therapeutics, Vol 9, No. 5; pg. 568-577 (1968)					
	CF	Fishman, et al., "Disposition of Naloxone-7,8- ³ H in Normal & Narcotic-Dependent Men"; J. of Pharm. and Experimental Therapeutics (1973) Vol 187, No. 3, pg. 575-580					
	CC	Fraser, Albert D., et al., "Clinical Toxicology of Drugs Used in the Treatment of Opiate Dependency"; Clinical Toxicology 1, (1990) Vol 10, No. 2, pg. 375-386					
	CH	Freye, et al., "Effects of Tramadol and Tilidine/Naloxone on Oral-Caecal Transit & Pupillary Light Reflex"; Arzneim.-Forsch/Drug Res. 30 (1) (2000) pg. 24-30					
	CH	Fudale, et al., "Effects of Burpenorphine and Naloxone in Morphine-Stabilized Opioid Addicts"; Drug and Alcohol Dependence 50 (1998) pg. 1-8					
	CJ	Fudale, et al., "Human Pharmacology and Abuse Potential of Nalmefene"; Clin Pharm and Thera (1991) Vol 49, 3, pg. 300-306					
	CK	Gel, et al., "Prolonged Blockade of Opioid Effect with Oral Nalmefene"; Clin Pharmacol Ther. (1986) pg. 537-542					
	CL	Gerra, et al., "Clonidine and Opiate Receptor Antagonists in the Treatment of Heroin Addiction"; J. Substance Abuse Treatment (1995) Vol 12, 1, pg. 35-41					
	CM	Ghodse, et al., "Opioid analgesics and narcotic antagonists"; Side Effects of Drugs (2000) Annual 23, Ch. 8, pg. 96-113					
	CN	Giatt, William, M.D. FACP, "A New Method for Detoxifying Opioid-Dependent Patients"; J. Substance Abuse Treatment (1999) Vol 17, No 3, pg. 193-197					
HS	CO	Gold, et al., "Rapid Opioid Detoxification during General Anesthesia"; Anesthesiology (1999) Vol 91, No 6, 1639-1647					
	CP	Greenwald, et al., "Comparative Clinical Pharmacology of Short-Acting <i>M</i> > <i>V</i> Opioids in Drug Abusers"; J. Pharm. and Experimental Therapeutics (1996) Vol 277, No 3, pg. 1228-1236					
EXAMINER <i>/Humera Sheikh/</i>				DATE CONSIDERED 01/21/2007			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 097781,081	10/300,906
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Ostlack, et al.		
						FILING DATE: February 6, 2007	GROUP: 1615	11/04/03
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	*NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	DA	8 9 4 0 5 6 7 :	07/10/1990	Jenkins, et al.	424	480		
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	DA						YES	NO
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
HS	DL	Gupta, et al., "Morphine Combined with Doxapram or Naloxone"; Anesthesia (1974) Vol 29 pg. 33-39						
	DE	Richter, et al., "Clinical Investigation on the Development of Dependence during Oral Therapy with Tramadol"; Arzneim-Forsch/Drug Res. 35 (No 11) (1985) pg. 1742-1744						
	DE	Rosen, et al., "Effect of Clonidine Pretreatment on Naloxone-Precipitated Opiate Withdrawal"; J. of Pharm. and Experimental Ther. (1996) Vol 276, No 3, pg. 1128-1135						
	DF	Rosen, et al., "The effect of lamotrigine on naloxone-precipitated opiate withdrawal"; Drug and Alcohol Dependence (1998) Vol 52, pg. 173-176						
	DG	Rosen, et al., "A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal"; European J. of Pharm. (1996) Vol 307, pg. 251-257						
	DF	Schuh, et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. of Pharm. and Experimental Ther. (1996) Vol 278, 2, pg. 836-846						
	DE	Schuh, et al., "Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans"; Psychopharmacology (1999) Vol 145, pg. 162-174						
	DJ	Stevens, et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions"; Psychopharmacology (1981) Vol 75, pg. 210-211						
	DE	Stine, et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug Alcohol Abuse (1994) Vol 20, (4), pg. 445-458						
	DL	Stine, et al., "Use of Drug Combinations in Treatment of Opioid Withdrawal"; J. of Clinical Psych. (1992) Vol 12, No. 3, pg. 203-209						
	DM	Stoller, et al., "Effects of buprenorphine/naloxone in opioid-dependent humans"; Psychopharmacology (2001) Vol 154, pg. 230-242						
	DF	Strain, et al., "Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. of Pharm. and Experimental Ther. (1992) Vol 261, No. 3, pg. 985-993						
	DG	Strain, et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pg. 374-383						
	DP	Strain, et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. of Pharm. and Experimental Ther. (1993) Vol 267, No 2, pg. 624-634						
↓	DQ	Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages						
HS	DR	Umbreit, et al., "Naltrexone shortened opioid detoxification with buprenorphine"; Drug and Alcohol Dependence (1999) Vol 56, pg. 181-190						
EXAMINER /Humera Sheikh/				DATE CONSIDERED			01/21/2007	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 097761,081	10/700,906	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Oshick, et al.	FILING DATE: February 8, 2001	GROUP: 1615	
U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HS	EA	0	0	7	0	Oshick	424	451	
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	EB								YES NO
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
HS	EC	Vaccarino, et al., "Endogenous Opiates: 1999"; Peptides 21 (2000) pg. 1975-2034							
	ED	Wang, et al., "Inverse agonists and neutral antagonists at μ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence"; J. of Neurochemistry (2001) Vol 77, pg. 1590-1600							
	EF	Wzy, et al., "Responsivity to Naloxone during Morphine Dependence"; Annals New York Academy of Sciences, pg. 252-261							
	EF	Weinberg, et al., "Sublingual absorption of selected opioid analgesics"; Clin Pharm Ther (1988) Vol 44, No 3, pg. 335-342							
	EG	Wells, et al., "In Vivo Pharmacological Characterization of SOR 9409, a Nonpeptide Opioid μ -Agonist/ δ -Antagonist that Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence"; J. Pharm and Exper. Thera. (2001) Vol 297, No 2, pg. 597-605							
	EH	Wodak, Alex, "Drug Treatment for Opioid Dependence", Australian Prescriber (2001) Vol 24, No 1, pg. 4-6							
	EI	Wright, et al., "Acute physical dependence in humans; repeated naloxone-precipitated withdrawal after a single-dose of methadone"; Drug and Alcohol Dependence (1991) Vol 27, pg. 139-148							
	EJ	Zhu, et al., "Naltrexone-precipitated morphine withdrawal in infant rat is attenuated by acute administration of NOS inhibitors but not NMDA receptor antagonists"; Psychopharmacology (2000) Vol 150, pg. 325-336							
	EK	Han, et al., "Mucoadhesive buccal disks for novel nalbuphine prodrug controlled delivery: effect of formulation variables on drug release and mucoadhesive performance"; International J. of Pharm (1999) Vol 177, pg. 201-209							
	EL	Handal, et al., "Naloxone"; Annals of Emergency Medicine (1983) Vol 12, pg. 438-445							
	EM	Harris, et al., "Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine"; Drug and Alcohol Dependence (2000) Vol 61, pg. 85-94							
↓	EM	Hawkes, et al., "Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine"; Aliment Pharm Ther (2001) Vol 15, pg. 625-630							
HS	EI	Högger, et al., "Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized crossover study in healthy human volunteers"; International J. Clin Pharm and Ther (1999) Vol 37, No 8, pg. 377-385							
EXAMINER /Humera Sheikh/					DATE CONSIDERED				01/21/2007
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>									

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09781,001			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)								APPLICANT(S): Oshlack, et al.				
								FILING DATE: February 6, 2004	11/04/03	GROUP: 1515		
U.S. PATENT DOCUMENTS												
*EXAMINER INITIAL		DOCUMENT NUMBER				DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	FA	4	9	9	1	3	3	9	01/22/1991	Kreek, et al.	514	282
HS	FE	4	9	9	G	3	1	1	02/05/1991	Goldie, et al.	424	484
HS	FC	5	9	1	1	8	1	6	12/10/1991	Malkowska, et al.	424	484
HS	FD	9	0	9	1	3	9	9	02/25/1992	Heafield, et al.	424	457
HS	FE	9	1	1	9	1	9	9	06/01/1993	Krishnamurthy	424	488
HS	FE	9	1	2	9	5	3	1	07/13/1993	Thompson, et al.	73	865.9
HS	FG	9	1	9	9	3	5	1	11/30/1993	Oshlack, et al.	424	468
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER				DATE	COUNTRY		CLASS	SUBCLASS	TRANSLATION	
		FI									YES	NO
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
HS	FI	Budd, Keith, "Clinical use of Opioid Antagonists", Bailliere's Clinical Anesthesiology (1987) Vol 1, No 4, pg. 993-1011										
	FJ	Crain, et al., "Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment", Proc. Natl. Acad. Sc (1995) Vol 92, pp. 10540-10544										
	FI	Howes, et al., "The Pharmacology of TR5109, a New Narcotic Agonist/Antagonist Analgesic", NIDA Research (1979) pg. 99-105										
	FE	Leedling, et al., "Disposition and metabolism of codorphone in the rat, dog and man", Drug Metabolism and Disposition (1982) Vol 10, No 6, pg. 649-653										
	FM	Amassa, et al., "Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet", Drug and Alcohol Dependence (2000) Vol 58, pg. 143-152										
	FN	Hussain, et al., "Buccal and oral bioavailability of naloxone and naltrexone in rats", (1987) Vol 36, pg. 127-130										
	FO	Jasinski, et al., "The human pharmacology and abuse potential of N-allylnormorphine naloxone", J. of Pharm and Exper Thera (1997) Vol 157, No. 2, pg. 420-425										
	FP	Jones, et al., "Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans", Drug and Alcohol Dependence (2000) Vol 60, pg. 29-37										
↓	-FO	Kanof, et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects", J. of Pharm and Exper Thera (1992), Vol 260, No. 1, pg. 355-363										
HS	FR	King, et al., "Naltrexone Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study", Alcoholism: Clin and Exp Res (1997) Vol 21, No. 5, pg. 906-909										
EXAMINER /Humera Sheikh/							DATE CONSIDERED			01/21/2007		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with NPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO: 200.1133	SERIAL NO: 09/781,087 10/700,906	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)								APPLICANT(S): Oshlack, et al.		
								FILING DATE: February 8, 2001 1404/03	GROUP: 1515	
U.S. PATENT DOCUMENTS										
*EXAMINER INITIAL		DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HS	GA	5	2	8	6	4	9	3	02/15/1994	Oshlack, et al. 424 468
HS	GB	5	3	2	4	3	5	1	06/28/1994	Oshlack, et al. 106 153
HS	GC	5	3	3	6	6	9	1	08/09/1994	Rafla, et al. 514 629
HS	GD	5	3	5	6	4	6	7	10/18/1994	Oshlack, et al. 106 153
HS	GE	5	4	1	1	7	4	5	05/02/1995	Oshlack, et al. 424 456
HS	GF	5	4	6	0	8	2	6	10/24/1995	Mennil, et al. 424 470
HS	GG	5	4	7	2	7	1	2	12/05/1995	Oshlack, et al. 424 460
FOREIGN PATENT DOCUMENTS										
		DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
HS	GH	8	7	0	1	2	8	2	03/12/1987	WO A61K 31/485 YES
HS	GI	0	1	3	2	1	8	0	05/10/2001	WO (A2) A61K 31/485 NO
HS	GJ	0	1	6	8	0	8	0	09/20/2001	WO (A2) A61K 31/00 NO
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)										
HS	GK	Kogan, et al., "Estimation of the Systemic Availability and other Pharmacokinetic Parameters of Naloxone in Man after Acute and Chronic Oral Administration"; Res. Commu. in Chem. Path. and Pharm (1977) Vol 18, No. 1; pg. 29-34								
HS	GL	Kosten, Thomas R., M.D., "Buprenorphine for Benzodiazepine-Abusing Heroin Addicts"; Amer J. of Psychiatry (1994) Vol 1, pg. 151								
HS	GM	Kosten, et al., "Opioid antagonist challenges in buprenorphine maintained patients"; Drug and Alcohol Dependence (1990) Vol 25, pg. 73-78								
HS	GN	Kurland, et al., "Naloxone and the Narcotic Abuser: A Controlled Study of Partial Blockade"; Inter. J. of the Addictions (1974) Vol 9, No. 5, pg. 663-672								
HS	GO	Lee, et al., "Nalbuphine Coadministered with Morphine Prevents Tolerance and Dependence"; Anesth Analg (1997) Vol 84, pg. 810-815								
HS	GP	Lehmann, et al., "Influence of Naloxone on the Postoperative Analgesic and Respiratory Effects of Buprenorphine"; Eur J. Clin. Pharm. (1988) Vol 34, 343-352								
HS	QQ	Levine, et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone"; J Clin Invest. (1988) Vol 82, pg. 1574 - 1577								
EXAMINER	/Humera Sheikh/				DATE CONSIDERED				01/21/2007	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09/781,081 10/300,906			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)								APPLICANT(S): Oshlack, et al.				
								FILING DATE: February 5, 2001 1/14/03	GROUP: 1615			
U.S. PATENT DOCUMENTS												
EXAMINER INITIAL		DOCUMENT NUMBER					DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	HA	5	4	2	5	5	2	2	12/26/1995	Sackler, et al.	424	489
HS	HB	5	5	5	5	2	2	2	03/19/1996	Oshlack, et al.	424	476
HS	HC	5	5	0	2	4	5	2	04/16/1996	Oshlack, et al.	424	468
HS	HD	5	5	0	8	5	5	2	04/16/1996	Krishnamurthy	424	484
HS	HE	5	5	0	5	0	5	2	08/27/1996	Oshlack, et al.	424	468
HS	HF	5	5	5	2	5	2	2	09/03/1996	Gauthier, et al.	514	489
HS	HG	5	0	5	5	4	5	2	01/07/1997	Miller, et al.	424	468
HS	HH	5	0	5	5	3	4	5	02/11/1997	Buxton, et al.	424	459
HS	HI	5	5	2	2	2	2	2	04/22/1997	Knott, et al.	424	494
HS	HJ	5	0	5	5	4	2	5	06/17/1997	Oshlack, et al.	424	459
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
										YES	NO	
	HK											
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
HS	HL	Loimer, et al., "Combined Naloxone/Methadone Preparations for Opiate Substitution Therapy"; J. of Substance Abuse Treatment (1991) Vol 8, pg. 157-160										
HS	HM	Martin, et al., "Bioavailability Investigation of a New Tildidine/Naloxone Liquid Formulation Compared to a Reference Formulation"; Arzneim.-Forsch./Drug Res. (1999) Vol 49, pg. 599-607										
HS	HN	Martin, et al., "Demonstration of Tolerance to and Physical Dependence on N-Allylnormorphine (Nalorphine)"; J. of Pharm and Exper Thera (1965) Vol 150, No. 3, pg. 437-442										
HS	HO	Mendelson, et al., "Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers"; Psychopharmacology (1999) Vol 141, pg. 37-46										
HS	HP	Mendelson, et al., "Buprenorphine and Naloxone Interactions in Methadone Maintenance Patients"; Society of Biological Psychiatry (1997) Vol 41, pg. 1095-1101										
HS	HQ	Nutt, et al., "Methadone-naloxone mixtures for use in methadone maintenance programs"; Clin Pharma and Thera, Vol 15, No. 2, pg. 156-166 (1974)										
HS	HR	Parwatikar, et al., "Methadone-naloxone in combination for the treatment of heroin addicts"; Clin Pharm and Thera, Vol 14, No. 6, pg. 941-948 (1973)										
EXAMINER <i>/Humera Sheikh/</i>							DATE CONSIDERED 01/21/2007					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09/981,968 10/700,906			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)								APPLICANT(S): Oshlack, et al.				
								FILING DATE: February 6, 2001 1/6/03	GROUP: 1615			
U.S. PATENT DOCUMENTS												
*EXAMINER INITIAL		DOCUMENT NUMBER					DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	IA	6	6	2	2	2	5	08/12/1997	Oshlack, et al.	424	495	
HS	IB	2	6	2	2	7	2	2	Buxton, et al.	424	495	
HS	IC	2	1	2	2	3	2	1	Sackler, et al.	424	490	
HS	ID	2	6	2	3	5	6	2	Oshlack, et al.	424	495	
HS	II	5	7	6	3	2	2	2	Miller, et al.	514	282	
HS	IF	6	7	2	0	4	2	9	Kim	514	282	
HS	IC	6	2	1	1	2	2	6	Krishnamurthy	424	498	
HS	II	5	2	3	6	2	2	1	Mioduszewski	514	282	
HS	II	6	8	4	6	6	6	1	Miller, et al.	424	484	
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER					DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
											YES	NO
	II											
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
HS	IK	Patwardikar, et al., "Naloxone-Methadone Combination for the Treatment of Opiate Dependence"; Missouri Institute of Psychiatry, pg. 1350-1354 (1973)										
HS	IL	Pitts, et al., "Antinociceptive and Response Rate-Altering Effects of Kappa Opioid Agonists, Spiradoline, Enadolines and U69,593, Alone and in combination with Opioid Antagonists in Squirrel Monkeys"; J. Pharm and Exper Ther (1994) Vol 271, No. 3, pg. 1501-1508										
HS	IM	Preston, et al., "Buprenorphine and Naloxone alone and in combination in opioid-dependent humans"; Psychopharmacology (1988) Vol 94, pg. 484-490										
HS	IN	Preston, et al., "Differential Naltrexone Antagonism of Hydromorphone and Pentazocine Effects in Human Volunteers"; J. Pharm and Exper Ther (1993) Vol 264, No. 2, pg. 813-823										
HS	IO	Preston, et al., "Effects of Sublingually given naloxone in opioid-dependent human volunteers"; Drug and Alcohol Dependence (1990) Vol 25, pg. 27-34										
HS	IP	Bigelow, et al., "Abuse Liability Assessment of Buprenorphine-Naloxone Combinations"; Dept. of Psychiatry and Behavioral Sciences The Johns Hopkins University School of Medicine, pg. 145-149 (2003)										
HS	IQ	Wikler, et al., 'N-Allylnormorphine: Effects of single doses and precipitation of acute "Abstinence Syndromes" during addiction to morphine, methadone or heroin in man (post-addict); N-Allylnormorphine During Narcotic Addiction (1953) pg. 8-20										
EXAMINER /Humera Sheikh/								DATE CONSIDERED 01/21/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE								ATTY. DOCKET NO.:	SERIAL NO.:		
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)										Oshlack, et al.	10700,906 09781,081		
										FILING DATE: February 6, 2001	GROUP: 1615		
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER					DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
HS	JE	5	3	1	9	1	1	0	12/15/1998	Miller, et al.	264	460	
HS	JE	5	3	?	9	0	1	1	02/09/1999	Wong, et al.	424	473	
HS	JE	5	3	1	5	7	1	8	03/09/1999	Hesfield, et al.	424	464	
HS	JD	5	3	?	1	1	1	1	04/06/1999	Miller, et al.	424	468	
HS	JE	8	1	0	8	1	1	1	06/01/1999	Miller, et al.	514	282	
HS	JF	5	1	8	3	8	1	1	09/28/1999	Oshlack, et al.	424	457	
HS	JG	5	1	5	8	8	8	8	09/28/1999	Chasin, et al.	424	490	
HS	JE	5	1	?	5	1	?	1	10/12/1999	Oshlack, et al.	424	457	
HS	JE	5	1	6	5	1	?	3	10/12/1999	Miller, et al.	424	468	
HS	JE	5	1	?	3	5	5	1	10/19/1999	Oshlack, et al.	424	457	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER					DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
											YES	NO	
	JK												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
HS	JE	Zaks, et al., "Naloxone Treatment of Opiate Dependence"; JAMA (1971) Vol 215, No. 13, pg. 2108-2110											
HS	JM	Barton, et al., "Intranasal Administration of Naloxone by Paramedics"; Prehospital Emergency Care (2002) Vol 6, No. 1, pg. 54-58											
HS	JN	Blachly, Paul, H., M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pg. 209-213											
HS	JO	Bashaw, et al., "Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade"; Inter J. of Clin Pharm and Thera (1995) Vol 33, No. 9, 524-529											
HS	JP	Jasinski, D.R., "Assessment of the Abuse Potentiality of Morphinelike Drugs (Methods Used in Man)"; Drug Addiction (1977) pg. 197-258											
HS	JQ	Johnson, et al., "Buprenorphine and Naloxone for Heroin Dependence"; Substance Use Disorders (2000) pg. 519-526											
HS	JP	Strain, et al., "Opioid antagonist effects of dezocine in opioid-dependent humans"; Clin Pharm and Thera (1996) Vol 60, No. 2, pg. 206-217											
EXAMINER		/Humera Sheikh/					DATE CONSIDERED		01/21/2007				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09/781,081 <u>10/700,906</u>			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									APPLICANT(S): Oshlack, et al.				
									FILING DATE: February 6, 2001 <u>11/14/03</u>	GROUP: 1615			
U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	KB	6	6	2	8	9	8	2	02/15/2000	Oshlack, et al.	424	476	
	KB	6	0	6	8	6	5	6	05/30/2000	Leslie, et al.	424	489	
	KC	6	6	8	7	8	3	8	06/20/2000	Milkowska, et al.	424	457	
	KD	6	0	6	3	8	3	3	06/20/2000	Oshlack, et al.	424	461	
	KE	6	1	6	3	8	5	6	08/15/2000	Simon,	424	449	
	KE	6	1	6	8	6	6	1	08/15/2001	Chasin, et al.	424	489	
	KC	6	6	6	8	8	8	8	11/07/2000	Sackler, et al.	424	489	
	KH	6	1	1	3	8	8	8	11/07/2000	Heafield, et al.	424	489	
	KB	6	1	6	2	1	6	6	12/19/2000	Miller, et al.	424	468	
	KE	6	6	1	0	8	8	6	04/03/2001	Oshlack, et al.	424	489	
	KK	6	8	8	8	8	8	7	07/03/2001	Miller, et al.	424	489	
	KL	6	8	6	8	5	8	6	07/03/2001	Oshlack, et al.	424	457	
HS	KM	6	8	9	1	1	8	5	09/25/2001	Oshlack, et al.	424	457	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES
HS	KN	6	1	8	7	7	8	5	05/31/2001	WO (A1)	A61K		
HS	KO	6	1	8	6	6	5	1	07/26/2001	WO (A1)	A61K	31/485	
HS	KB	6	1	6	5	6	8	6	11/15/2001	WO (A2)	A61P		
HS	KO	6	6	9	8	8	8	6	11/15/2001	WO (A2)	A61K	31/00	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
HS	KR	Presion, et al., "Abuse liability studies of opioid agonist-antagonists in humans"; Drug and Alcohol Dependence (1991) Vol 28, pg. 49-82											
HS	KS	Brennscheidt, et al., "Pharmacokinetics of Nortilidine and Naloxone after Administration of Tilidine/Naloxone Solution or Tilidine/Naloxone Sustained Release Tablets"; Arzneim.-Forsch./Drug Res. (2000) Vol 50, pg. 1015-1022											
EXAMINER: <u>/Humera Sheikh/</u>									DATE CONSIDERED <u>01/21/2007</u>				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO.: 200.1133	SERIAL NO.: <u>09/781,081</u> <u>10/700,906</u>			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)								APPLICANT(S): Oshlack, et al.				
								FILING DATE: <u>February 8, 2001</u> <u>11/04/03</u>	GROUP: 1615			
U.S. PATENT DOCUMENTS												
*EXAMINER INITIAL		DOCUMENT NUMBER					DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	LA	9	9	9	6	9	9	8	10/23/2001	Oshlack, et al.	424	468
HS	LB	9	9	2	9	9	2	7	12/04/2001	Miller, et al.	424	468
HS	LC	6	3	9	9	0	9	3	01/01/2002	Oshlack, et al.	424	457
HS	LD	9	9	7	5	9	9	7	04/23/2002	Kaiko, et al.	424	400
HS	LE	6	9	9	2	9	9	2	05/14/2002	Oshlack, et al.	424	480
HS	LF	6	3	9	9	0	9	2	06/04/2002	Miller, et al.	424	464
HS	LG	9	9	2	9	9	9	2	11/05/2002	Kaiko, et al.	424	400
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER					DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
											YES	
	U										NO	
	U											
	LF											
	LK											
	U											
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
LM												
LN												
LO												
LK												
EXAMINER	/Humera Sheikh/					DATE CONSIDERED			01/21/2007			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09/781,981-10/70,916					
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									APPLICANT(S): Curtis Wright et al.						
									FILING DATE: February 8, 2001 /1/04/03		GROUP: 1615				
U.S. PATENT DOCUMENTS															
*EXAMINEE INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
HS	AA	5	6	9	6	1	3	0	12/99	Mitch et al.	514	210.16			
	AW	5	9	1	2	0	5	0	10/99	Foss	514	282			
	AC	5	6	8	1	4	2		10/99	Reder et al.	424	449			
	AN	5	6	1	2	1	4	1	6/98	Chasin et al.	424	426			
	AE	5	9	8	0	1	3	2	3/99	Hill	514	282			
	AF	5	6	6	6	1	1	1	2/99	Kuczynski et al.	424	472			
	AO	5	6	0	0	9	1	0	2/99	Demopoulos et al.	604	49			
	AP	5	6	0	8	0	0	2	2/99	Demopoulos et al.	604	890.1			
V	AN	5	7	0	7	1	2	5	6/98	Crain et al.	514	282			
HS	AJ	5	6	0	0	2	5	0	5/97	Qin et al.	514	282			
	AP	5	6	2	0	1	3	2	2/97	Qin et al.	514	282			
FOREIGN PATENT DOCUMENTS															
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
														YES	NO
HS	AL	19	6	5	1	1	5	1	6/98	DE	A61K	31/485			
HS	AM	29	7	1	0	2	0	1	2/97	DE	A61K	31/485			
HS	AN	4	3	2	0	0	0	0	2/95	DE	A61K	31/485			
HS	AO	2	7	2	2	0	3	0	11/72	DE	A61K	27/00			
HS	AP	5	6	0	0	0	0	2	6/99	EP	A61K	31/485			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)															
HS	AC	Abstract, Cancer Chemother Pharmacol (1998); 42(4):287-91.													
HS	AN	Yuan et al., Drug and Alcohol Dependence (1998); 52:161-165.													
HS	AS	Gan et al., "Opioid-Sparing Effects of a Low-Dose Infusion of Naloxone in Patent-Administered Morphine Sulfate," Anesthesiology (1997), 87(9):1075-1080.													
EXAMINER /Humera Sheikh/									DATE CONSIDERED		01/21/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.															

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE								ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09/781,064 10/700 A06		
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)										APPLICANT(S): Curtis Wright et al.			
										FILING DATE: February 6, 2004 <i>y/04/03</i>		GROUP: 1615	
U.S. PATENT DOCUMENTS													
*EXAMINE R INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	BB	6	5	1	5	6	5	1	4/97	Khanna et al.	514	399	
	BB	5	5	0	5	0	4	5	12/96	Crain et al.	514	12	
	BG	5	5	8	5	0	2	5	12/96	Crain et al.	514	282	
	BE	5	5	2	8	7	2	5	12/96	Portoghesse et al.	546	35	
	BE	5	5	2	6	5	5	2	12/96	Rose et al.	514	343	
	BF	5	5	5	5	5	3	5	9/96	Mayer et al.	514	25	
	BG	5	5	3	6	4	5	2	4/96	Aston et al.	514	608	
	BH	5	5	2	4	5	5	0	9/96	Weber et al.	514	249	
▼	BI	5	0	1	2	5	2	5	4/96	Crain et al.	514	282	
	BJ	5	5	0	2	0	5	0	9/96	Mayer et al.	514	249	
HS	BK	5	4	0	0	3	5	2	1/96	Kitchell et al.	424	426	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
HS	BI	5	5	4	2	4	4	0	4/95	EP	A61K	31/485	
HS	BM	0	3	0	2	0	0	1	4/96	EP	A61K	31/485	
HS	BN	0	2	0	0	2	0	2	12/96	EP	A61K	9/22	
HS	BO	5	0	0	2	1	2	0	7/99	WO	A61K	31/485	
HS	BP	5	5	3	5	6	2	5	4/96	WO	A61K	31/485	
OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, Etc.)													
HS	BQ	Shen et al., "Ultra-Low Doses of Naltrexone or Etorphine Increase Morphine's Antinociceptive Potency and Attenuate Tolerance/Dependence in Mice." Brain Research (1997), 757:176-190.											
HS	BR	Yuan et al., Clinical Trials and Therapeutics (1997), 61:467-475.											
EXAMINER /Humera Sheikh/								DATE CONSIDERED		01/21/2007			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081 <u>10/700,906</u>			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									APPLICANT(S): Curtis Wright et al.					
									FILING DATE: February 8, 2001 <u>11/04/03</u>		GROUP: 1615			
U.S. PATENT DOCUMENTS														
*EXAMINE R INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	CB	5	4	2	2	5	8	3	12/95	Crain et al.	514	12		
	CB	5	4	5	2	2	0	5	12/95	Portoghesi et al.	546	35		
	CC	5	4	2	5	4	4	2	6/95	Zagon et al.	514	282		
	CC	5	3	2	6	8	5	2	12/94	Ockert	514	282		
	CE	5	2	5	5	5	0	5	10/94	Bihari et al.	514	282		
	CF	5	2	5	2	8	8	3	10/94	Mayer et al.	514	289		
	CG	5	3	5	2	8	8	5	12/94	Portoghesi et al.	514	279		
	CH	5	3	2	1	0	1	2	6/94	Mayer et al.	514	25		
	CI	5	3	1	7	0	2	2	5/94	Borsodi et al.	514	282		
▼	CJ	5	3	4	6	2	8	5	5/94	Rose et al.	424	10		
HS	CP	5	2	2	2	2	8	5	12/93	Oshlack et al.	424	486		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
HS	CI	9	2	3	3	5	6	6	3/94	WO	A61K	9/20		
HS	CM	5	5	5	2	2	8	4	2/96	WO	A61K	31/485		
HS	CN	9	3	0	3	8	0	4	2/95	WO	A61K	31/485		
HS	CO	5	4	0	6	4	2	5	3/94	WO	A61K	31/46		
HS	CP	8	3	0	2	1	8	2	9/83	WO	A61K	9/22		
OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, Etc.)														
HS	CQ	Mendelson J., et al, "Buprenorphine and Naloxone Interactions in Opiate-Dependent Volunteers," Clin. Phar. Ther. 1996, 60:105-114.												
HS	CR	Walsh et al., "Effects of Naltrexone on Response to Intravenous Cocaine, Hydromorphone and their Combination in Humans," 1996.												
EXAMINER /Humera Sheikh/										DATE CONSIDERED 01/21/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE								ATTY. DOCKET NO.: 200.1133	SERIAL NO.: 09/784,881 <u>10/30/906</u>			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)										APPLICANT(S): Curtis Wright et al.				
										FILING DATE: February 8, 2001 <u>11/04/03</u>	GROUP: 1615			
U.S. PATENT DOCUMENTS														
*EXAMINE R INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	DA	8	2	8	6	8	6	8	10/93	Askanazi et al.	514	282		
	DB	8	2	8	6	7	1	4	8/93	Lee et al.	424	449		
	DC	8	7	7	5	5	6	5	7/93	London et al.	514	535		
	DD	8	1	5	9	5	3	8	9/92	Granger et al.	424	449		
	DE	5	7	0	2	8	6	7	4/92	Goldberg	514	282		
	DF	8	0	8	5	7	1	8	9/92	Sinclair	424	449		
	DC	8	5	8	5	0	6	5	2/92	Sinclair et al.	514	282		
	DH	8	0	2	6	3	4	7	12/91	Mendelson et al.	514	282		
	DI	4	8	3	5	4	2	5	6/90	Lewis	514	282		
HS	DJ	5	8	8	6	8	6	0	12/89	Rzeszotarski et al.	514	282		
	HS	DF	4	5	8	7	5	6	5	11/89	Sinclair	514	282	
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES
	DL													NO
OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, Etc.)														
HS	DM	Chih-Cheng Chien, Neuroscience Letters 190 (1995), 137-139.												
HS	DN	Crain et al., "Ultra-Low Concentrations of Naloxone Selectively Antagonize Excitory Effects of Morphine on Sensory Neurons, Thereby Increasing Its Antinociceptive Potency and Attenuating Tolerance/Dependence During Chronic Cotreatment," Proc. Natl. Acad. Sci. USA (1995), 92:10540-10544.												
HS	DO	Hanecon, Analgesic, Antipyretic and Anti-Inflammatory Drugs in Remington's Science and Practice of Pharmacy (1995), 2:1207.												
HS	DP	Physician's Desk Reference 48 th Ed. (1994) Montvale, NJ, 2120-2121.												
HS	DO	Foss et al., J. Clin Pharmacol (1993), 33:747-751.												
EXAMINER <u>/Humera Sheikh/</u>								DATE CONSIDERED <u>01/21/2007</u>						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200.1133	SERIAL NO.: <u>09/781,981</u> <u>10/700,906</u>			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									APPLICANT(S): Curtis Wright et al.				
									FILING DATE: February 8, 2001 <u>11/04/03</u>	GROUP: 1615			
U.S. PATENT DOCUMENTS													
*EXAMINE R INITIAL		DOCUMENT NUMBER						DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HS	EA	5	4	7	5	4	7	8	10/89	Fishman et al.	412	10	
	EB	5	4	8	5	5	8	5	8/89	Goldberg	514	282	
	EG	5	8	6	1	5	5	8	8/89	Oshlack et al.			
	ED	4	6	0	6	5	4	8	2/89	Wuest et al.	514	381	
	EB	4	8	0	8	4	4	3	2/89	Choi	514	464	
	EF	4	8	0	4	3	4	4	2/89	Chien et al.	424	448	
	EG	4	6	0	8	2	6	8	2/89	Pasternak	514	282	
	EH	4	7	4	4	4	6	0	11/88	Kresek et al.	514	282	
↓	EI	4	7	8	9	3	7	4	8/89	Kresek et al.	514	282	
HS	EJ	4	7	8	0	0	5	5	2/89	Rzeszotarski et al.	514	282	
	EB	4	7	3	0	4	4	6	8/89	Portoghesi et al.	546	45	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
	EL												
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
HS	EN	Holmes et al., Anesth. Analg. (1993), 77:1166-73.											
HS	EN	Miaskowski et al., Brain Research (1992), 596:41-45.											
HS	EO	Weinhold et al., "Buprenorphine Alone and In Combination with Naltrexone in Non-Dependent Humans," Drug and Alcohol Dependence (1992), 30:263-274.											
HS	EP	Cappel et al., Pharma. Biolog. & Behav. (1989), 34:425-427.											
HS	EQ	Vaccarino et al., Pain (1989), 36:103-109.											
HS	ER	Gonzalez et al., "Naltrexone: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Opioid Dependence," Drugs (1988), 35:192-213.											
EXAMINER /Humera Sheikh/									DATE CONSIDERED 01/21/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200-1133	SERIAL NO.: 09/781,081 10/700,986			
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)									APPLICANT(S): Curtis Wright et al.				
									FILING DATE: February 6, 2001 11/04/03		GROUP: 1615		
U.S. PATENT DOCUMENTS													
*EXAMINE R INITIAL		DOCUMENT NUMBER					DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
HS	FB	1	7	1	1	1	1	5	1/88	Goldberg	514	260	
	FB	1	6	1	1	1	1	7	4/87	Lewis et al.	514	260	
	FC	1	6	0	6	3	1	6	8/86	Pasternak	514	260	
	FD	1	6	6	2	3	3	6	4/86	Lewis et al.	514	260	
	FC	1	6	7	3	1	6	6	3/86	Chen et al.	604	260	
	FF	4	1	6	1	3	7	6	8/84	Hussain et al.	424	260	
	FC	1	1	6	7	1	3	3	7/84	Gordon et al.	424	260	
	FH	4	4	1	1	1	1	1	5/84	Ganti	424	260	
V	FI	1	1	0	1	6	7	2	8/83	Portoghesi et al.	424	260	
HS	FJ	4	1	7	6	1	5	6	11/79	Goldberg	424	260	
	FB	3	9	6	6	6	1	0	6/76	Pachter et al.	424	260	
FOREIGN PATENT DOCUMENTS													
		DOCUMENT NUMBER					DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
											YES	NO	
	FI												
OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, Etc.)													
HS	FM	Sunshine, et al., "Analgesic Efficacy of Pentazocine Versus a Pentazocine-Naloxone Combination Following Oral Administration," Clin. J. Pain (1988), 4:35-40.											
HS	FN	Wang et al., "Crossover and Parallel Study of Oral Analgesics," J. clin. Pharmacol (1981), 21:162-168.											
	FO												
	FP												
	FQ												
	FR												
EXAMINER		/Humera Sheikh/					DATE CONSIDERED		01/21/2007				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							ATTY. DOCKET NO.: 200-1133	SERIAL NO.: 09/784,681- <u>10/300,970</u>		
		LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)							APPLICANT(S): Curtis Wright et al.			
									FILING DATE: February 8, 2007 <u>1/04/03</u>	GROUP: 1615		
U.S. PATENT DOCUMENTS												
*EXAMINEE INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HS	GA	3	8	7	5	5	5	4/75	Pachter et al.	424	260	
HS	GA	3	7	7	3	5	5	11/73	Pachter et al.	424	260	
HS	GC	3	6	7	5	5	5	2/70	Lachman et al.	424	260	
HS	GD	3	5	5	3	5	5	7	Lewenstein et al.	424	260	
HS	GE	3	3	3	7	5	5	7/67	Blumberg et al.	260	260	
HS	GF	7	7	7	5	5	6	9	Fromherz et al.	167	65	
	GC											
	GH											
	GI											
	GL											
	GF											
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
										YES	NO	
	GL											
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)												
	GM											
	GN											
	GO											
	GP											
	GQ											
	GP											
	GS											
EXAMINER /Humera Sheikh/							DATE CONSIDERED 01/21/2007					
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Curtis WRIGHT, et al.

FILING DATE: February 10,
2001 *4/04/03*

GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HS	AA	6	2	2	8	8	6	3	05/08/01	Palermo et al.	514	282
HS	AB	8	2	7	7	3	8	4	08/21/01	Kaito et al.	424	400

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	
HS	AC	WO	98	2	5	6	1	3	06/18/98	EPO	A61K	31/485	Abstract	
HS	AD	WO	00	3	8	6	4	9	07/06/00	EPO	A61K	9/00	Abstract	

OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, Etc.)

HS	AE	Press Release entitled "International Patent Application To Be Published on Abuse-Resistant Pain Reliever Being Developed by Purdue Pharma" August 8, 2001.
HS	AF	Paronis, et al., Increased Analgesic Potency of Mu Agonists after Continuous Naloxone Infusion in Rats, J Pharm. Exper. Ther. 1991 259(2) pg 582-589
HS	AG	Yoburn, et al., Supersensitivity to Opioid Analgesics Following Chronic Opioid Antagonist Treatment: Relationship to Receptor Selectivity, Pharmacol. Bio. Beh. 1995 51 (2) pg 525-529
HS	AH	Crain, et al., Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naloxone, unmasking potent opioid analgesia, Brain Res. 2001 888 pg 75-82
HS	AI	Zhang, et al., Down-Regulation of μ -Opioid Receptors in Rat and Monkey Dorsal Root Ganglion Neurons and Spinal Cord After Peripheral Axotomy, Neuroscience 1998 82, pg 223-240
HS	AJ	Abdulla, et al., Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons, J. Neuro Sci 1998 18, pg 9685-9694
HS	AK	Di Giandomario, et al., Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats, Neurosci. Lett. 1999 272, pg 163-186
HS	AL	Cicconeopoli, et al., Effect of nociceptin/orphanin FQ on the rewarding properties of morphins, Eur. J. Pharmacol. 2000 404, pg 153-159
	AM	
	AN	
EXAMINER	<i>/Humera Sheikh/</i>	
	01/21/2007	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 200.1133

SERIAL NO.: 09/784,581

10/700, 2016

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Curtis WRIGHT, et al.

FILING DATE: February 8, 2001

4/04/08

GROUP: 1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
------------------	-----------------	------	------	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

HS	AA	Bentley, Function of Myocardial α -ADRENOCEPTORS: Life Sciences (1982) Vol. 31 pg 101-112
HS	AE	Levine, et al., Potentiation of Pentazocine Analgesia by Low-dose Naloxone: J. Clin. Invest. (1988) Vol. 82 pg. 1574-1577
HS	AC	Yoburn, et al., Opioid Antagonist-induced Receptor Upregulation: Effects of Concurrent Agonist Administration, (1994) [Publication Date]: Brain Research Bulletin, Vol. 33 pg 237-240
HS	AD	Bunzow, et al., Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a μ , δ or κ opioid receptor type: FEBS Letters 347 (1994) pg. 284-288
HS	AE	Mollerau, et al., ORL1, a novel member of the opioid receptor family: Cloning, functional expression and localization: FEBS Letters 341 (1994) pg. 33-38
HS	AF	Wang, et al., cDNA cloning of an orphan opiate receptor gene family member and its splice variant: FEBS Letters 348 (1994) 75-79
HS	AG	Suzuki, et al., Morphine conditioned place preference after chronic treatment with naloxone in the rat: Research Communications in Substances of Abuse, (1991) Vol. 12, No. 3 pg. 119-131

EXAMINER	/Humera Sheikh/	DATE CONSIDERED	01/21/2007
----------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE								ATTY. DOCKET NO.: 200.1133CNS	SERIAL NO.: 10/700,906			
SEARCHED & INDEXED PATENT & TRADEMARK OFFICE (Use several sheets if necessary)		APPLICANT(S): Benjamin OSHLACK et al.												
		FILING DATE: November 4, 2003								GROUP: <i>To-be-assigned</i>	16/5			
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
HS	AA	4	5	8	7	1	1	8	05/09/1986	Hsiao	424	459		
	AB													
	AC													
	AD													
	AE													
	AF													
	AG													
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
HS	AH	04	0	5	2	3	4	6	06/24/04	WO (A1)	A61K	9/62	YES	NO
HS	AI	0	5	4	8	4	4	8	09/08/2000	EP (B1)	A61K	9/50	abstract	
	AJ													
	AK													
	AL													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
AM														
AN														
AO														
AP														
AQ														
AR														
AS														
EXAMINER /Humera Sheikh/								DATE CONSIDERED 01/21/2007						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.113C0N5SERIAL NO.:
10/700,906

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Benjamin OSHLACK et al.FILING DATE:
November 4, 2003GROUP:
1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER		DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA							
	AB							
	AC							
	AD							
	AE							
	AF							
	AG							

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
		YES	NO										
HS	AH	1	3	9	0	7	7	2	04/16/1975	GB	A61K31	485	
	AI												
	AJ												
	AK												
	AL												

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AM	
AN	
AO	
AP	
AQ	
AR	
AS	

EXAMINER

/Humera Sheikh/

DATE CONSIDERED

01/21/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.